A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China

Anhui Provincial Hospital, Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, Beijing Municipality, China

The Fifth Medical Center of the PLA General Hospital, Beijing, Beijing Municipality, China

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China

Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China

Harbin Medical University Affiliated Cancer Hospital, Harbin, Heilongjiang, China

Henan Provincial Cancer Hospital, Zhengzhou, Henan, China

The First Affiliated Hospital of Henan Medical University, Zhengzhou, Henan, China

Wells Prince Hospital of The Chinese University of Hong Kong, Hong Kong, Hong Kong, China

Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China

Jiangxi Cancer Hospital, Nanchang, Jiangxi, China

Jilin University First Hospital, Changchun, Jilin, China

Liaoning Cancer Hospital, Shenyang, Liaoning, China

Shanghai Gaobo Tumor Hospital, Shanghai, Shanghai Municipality, China

Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China

Tianjin Medical University Cancer Hospital, Tianjin, Tianjin Municipality, China

Shao Yi Fu Hospital, Affiliated to the School of Medicine of Zhejiang University, Hangzhou, Zhejiang, China